

Interim report January–September 2025



Surgical Science is a global leader in evidence-based medical simulation. The company's virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room – enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.

Surgical Science has approximately 330 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Seattle and Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.

Progress in the right direction

Third quarter 2025 (July – September)

- Net sales amounted to SEK 263.6 (231.8) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 19 percent.
- Sales of SEK 18.8 million from Intelligent Ultrasound are included in the figures. For comparable units, sales increased by 6 percent.
- License revenue amounted to SEK 65.5 (65.0) million and accounted for 25 (28) percent of net sales.
- The gross margin was 65 (69) percent.
- Operating profit amounted to SEK 27.2 (45.8) million. The profit includes SEK 1.5 million in restructuring costs attributable to the acquisition of Intelligent Ultrasound. Currency effects of SEK -7.2 million (-2.1) are recognized on the line Other operating income and costs.
- Net profit amounted to SEK 20.4 (43.0) million, corresponding to earnings per share of SEK 0.40 (0.84).
- Cash flow from operating activities amounted to SEK -4.4 (22.1) million. As at September 30, 2025, cash and cash equivalents amounted to SEK 597.4 (666.3) million.

First nine months of 2025 (January – September)

- Net sales amounted to SEK 723.5 (632.5) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 20 percent.
- For comparable units, sales increased by 5 percent.
- License revenue amounted to SEK 208.3 (195.3) million and accounted for 29 (31) percent of net sales.
- The gross margin was 66 (68) percent.
- Operating profit amounted to SEK 28.7 (105.2) million. Profit includes SEK 22.6 million in acquisition costs and SEK 5.3 million in restructuring costs, both of which are attributable to the acquisition of Intelligent Ultrasound. Currency effects of SEK -30.2 million (5.5) are recognized on the line Other operating income and costs.
- Net profit amounted to SEK 33.6 (95.4) million, corresponding to earnings per share of SEK 0.66 (1.87).
- Cash flow from operating activities amounted to SEK 6.9 (80.6) million.
- Intelligent Ultrasound, which operates in the field of ultrasound simulation, was acquired in February. The acquisition date was February 18.

Key figures

	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Net sales, SEK million	723.5	632.5	263.6	231.8	884.1
Operating profit (EBIT), SEK million	28.7	105.2	27.2	45.8	144.3
Operating profit (EBIT) excluding acquisition and restructuring costs, SEK million	56.6	105.2	28.7	45.8	144.3
Adjusted EBIT, SEK million	46.1	123.4	32.8	51.8	168.7
Adjusted EBIT margin, %	6.4	19.5	12.4	22.4	19.1
Adjusted EBIT margin, excluding acquisition and restructuring costs, %	10.2	19.5	13.0	22.4	19.1
Profit after financial items, SEK million	57.6	118.7	30.1	53.0	158.1
Net profit, SEK million	33.6	95.4	20.4	43.0	131.6
No. employees at end of period	328	270	328	270	274
Equity/assets ratio, %	91.4	92.6	91.4	92.6	88.1
Earnings per share, SEK	0.66	1.87	0.40	0.84	2.58
Equity per share, SEK	84.27	87.19	84.27	87.19	94.63
Share price on the balance sheet date, SEK	87.95	126.90	87.95	126.90	155.90
Market value on balance sheet date, SEK million	4,487.8	6,475.2	4,487.8	6,475.2	7,955.0

For definitions, see page 22.

A message from the CEO

Q3 was a clear step in the right direction for Surgical Science. Total sales of SEK 264 million was all-time high for the company. This was despite a negative impact on sales from currencies of 5 percentage points. The group grew by 14 percent compared to the same quarter last year, and by 19 percent adjusted for currency effects.

Profitability, adjusted EBIT, amounted to SEK 33 (52) million and was negatively impacted by restructuring costs of SEK 2 million. Adjusted for these costs, profitability was 13 (22) percent. We can see that the measures we launched six months ago to improve profitability are now beginning to have an effect.

Customer activity was high in Educational Products and very high in Industry/OEM, where we saw a strong inflow of development projects from both medical device companies and robotics companies.

Educational Products

Educational Products stabilized during the quarter, with growth of 8 percent compared to the same quarter in 2024 and 26 percent compared to the previous quarter. However, sales declined by 6 percent adjusted for sales attributable to Intelligent Ultrasound. Although we have set higher sales targets in this area, we can generally see a positive trend during the quarter.

We are seeing good demand and customer activity in several regions, with Europe showing the strongest growth during the quarter at 46 percent. The entire ultrasound simulation segment, which became a strategic focus area in connection with the acquisition of Intelligent Ultrasound, also developed positively with high customer demand in all markets except the UK. In the UK, we continue to see problems with the allocation of funds from the NHS – a key source of funding for our products – which had a negative impact on sales in this market.

The Americas grew by 9 percent, which was lower than our expectations and, as in previous quarters, was due to extended sales cycles in a tougher budgetary climate for hospitals. Sales in the US for comparable units (excluding sales derived from Intelligent Ultrasound) decreased.

During the quarter, we saw two prominent associations launch training programs that include certification based on simulators from Surgical Science. Together with the American Society for Gastrointestinal Endoscopy (ASGE), we launched a plan for training and certification in diagnostic endoscopy,



based on our GI Mentor simulator. In addition, our RobotiX Mentor robotic surgery simulator now includes the GESEA curriculum from the European Academy of Gynaecological Surgery's recognized framework for training in robotic surgery. These are two important steps in our work to make simulation a widely used and recognized tool in the training and certification of physicians and healthcare personnel. The result will be increased overall demand for the products required for certification, and customers will find it easier to obtain budgetary approval for these products.

Industry/OEM

Industry performed well during the quarter, with sales increasing by 20 percent. Development revenue increased by 131 percent compared with the same quarter in 2024, and the business area saw a strong inflow of new development projects, both in Medical Device Simulation and Robotics.

In the Medical Device Simulation area, we secured what is potentially the largest single deal in the company's history in this segment during the quarter, with one of the world's largest medical device companies. The deal spans four years and covers the development and delivery of simulators to be used in the customer's training and sales activities. In addition to this, we signed another large order with the same customer during the quarter, which proves our ability to sell multiple broad projects to the same customer.

"Our goal is to significantly improve the profitability of Educational Products. We are seeing that these initiatives are starting to have an effect."

In the Robotics product area, our recently launched product, RobotiX Express, has been very well received in the market. RobotiX Express is a simulator for surgeons to become proficient in robotic surgery. It is a powerful device for advanced simulation in a portable format, allowing it to be easily moved around to where it is needed. Demand for training in robotic surgery is very strong and is expected to increase further in the coming years as hospitals increasingly switch to this type of minimally invasive surgery. With RobotiX Express, Surgical Science is lowering the entry barrier and improving accessibility to training, independent of the robot console. RobotiX Express will be sold as a generic platform within Educational Products, but can also be customized for our various customers in robotic surgery to provide them with a portable and powerful platform for training and marketing. Our ability to offer a solution to the training challenge faced by robotics companies will enable more surgeons to be trained more effectively in this field.

License revenue for the third quarter amounted to SEK 66 (65) million, which is a slight increase compared with the same period in the preceding year, despite a stronger Swedish krona. Sales accounted for 25 (28) percent of the company's total revenue.

Intuitive, one of Surgical Sciences' largest customers, reported 19 percent procedure growth for the da Vinci system in the third quarter, exceeding market expectations. The installed base grew by 13 percent, primarily driven by the new da Vinci 5 platform. In the US, we continued to see a decline in simulation subscribers on older-generation da Vinci systems due to them being replaced with the new platform. An important comment from Intuitive is that the reconditioned fourth generation systems that are being replaced (da Vinci Xi and da Vinci X) will be resold, both in the US and internationally. This creates opportunities for hospitals that previously lacked the financial resources, to start robotic surgery programs. Furthermore these customers are expected to have significant training needs.

For the second quarter in a row, our revenue from new robot manufacturers remained at a low level. However, at the beginning of the fourth quarter of 2025, we are once again seeing stronger sales to these customers. Our license revenue varies from quarter to quarter, depending on when customers choose to place their license orders with Surgical Science.

Several regulatory announcements were made during the quarter, which strengthens the outlook for growth in robotic surgery. Among other things, Intuitive received CE approval for

da Vinci 5 in Europe and regulatory approval in South Korea, which is a significant market. Intuitive also received additional FDA clearance for a number of software updates on the da Vinci 5 in the US. Medtronic received CE approval in the EU for its important LigaSure Vessel Sealer device for the Hugo robot, and continued to publish study data that is expected to form the basis for FDA approval within approximately six months. Meanwhile, Chinese manufacturers of surgical robots continue to take regulatory steps outside China as well, such as Shurui, whose single-port robot has now been approved for sale in the EU.

Overall, we note that several of our customers in robotic surgery are approaching commercial launches, which is expected to lead to an increase in license revenue in the coming quarters and years.

Costs and results

The gross margin amounted to 65 (69) percent. One of the reasons for the decline is the very strong simulator sales in relation to license revenue, which thus accounted for a lower share of total sales than in the corresponding period last year.

For several quarters now, we have been pursuing a number of initiatives to improve profitability within Educational Products. Our goal is to significantly improve profitability in this area. We are seeing that these initiatives are beginning to have an effect, despite the headwinds from currency effects. Over the coming quarters and in 2026, I expect continued positive results.

Objectives and priorities

We see continued rapid development of the company in a dynamic market where we can see positive signals both in our external work with our customers and in our internal efforts to create a stronger, more efficient, and profitable company.

The strategic review that began before the summer is in its final stages. The strategy, which will lay the foundation for Surgical Science's continued growth journey, will be presented during our Capital Markets Day on December 8.

The strategy seeks to continue growing the company both in segments where Surgical Science has traditionally been strong, but also in new, adjacent segments with low penetration of simulation, where we see that our technology and expertise can create significant customer value. The result will be a company with more revenue streams that addresses a significantly larger market than today.

With our team, our position, technology, and strong momentum, I'm optimistic about the future development of Surgical Science.

Gothenburg, November 2025

Tom Englund

Tom Englund, CEO

Third quarter 2025 (July – September)


Net sales

Net sales for the third quarter of the year amounted to SEK 263.6 (231.8) million, an increase of 14 percent compared with the same period in the preceding year. Calculated in local currencies, sales increased by 19 percent.

A consequence of a more uncertain and cautious market climate is that the time it takes for quotes to turn into orders is increasing. In respect of simulator revenue, this resulted in many orders being placed toward the end of the second quarter. These could not be produced and distributed, which means that the order book at the end of the quarter was approximately SEK 30 million higher than at the beginning of the quarter. These orders were relatively evenly distributed between Educational Products and Industry/OEM. Most of the orders were shipped during the third quarter, and there is no significant difference between the opening and closing order book excluding this item after the third quarter.

Of the sales for the quarter, SEK 139.0 (128.3) million consisted of sales within the Educational Products business area and SEK 124.7 (103.6) million within the Industry/OEM business area.

Revenue by revenue stream



Net sales for Intelligent Ultrasound of SEK 18.8 million are included in sales for the third quarter of 2025 and are recognized exclusively within the Educational Products business area. For comparable units, sales increased by 6 percent.

As of 2025, note 2 on page 19 has been revised and expanded. Sales have been divided by product group, regardless of the business area from which they originate. Sales in Intelligent Ultrasound are included in their entirety in the ultrasound product group.


Educational Products

Sales in Educational Products increased by 8 percent, but decreased by 6 percent when excluding sales originating from Intelligent Ultrasound. Simulator sales amounted to SEK 120.1 (109.1) million and service revenue to SEK 18.9 (19.2) million.

The Asia region declined by 5 percent compared with the same quarter last year. Sales in China were stronger than in the first and second quarters and in line with the comparison period, while they declined in India. Sales from Intelligent Ultrasound for the region were SEK 0.5 million.

Sales in Europe remained strong, increasing by 46 percent. Strong sales were reported in countries such as the Czech Republic, Poland, and Portugal. Sales from Intelligent Ultrasound for the region were SEK 6.5 million.

Revenue by business area



The North and South America region increased by 9 percent compared with the corresponding quarter last year. Sales from Intelligent Ultrasound for the region amounted to SEK 9.7 million, which means that sales decreased for comparable units. This is mainly attributable to the US, which contracted by 25 percent (excluding sales from Intelligent Ultrasound). Brazil delivered strong sales.

The region Other contracted by 57 percent compared to a strong comparative quarter. Sales from Intelligent Ultrasound for the region were SEK 2.1 million.

In terms of sales per region, in general these vary markedly between different countries and periods within Educational Products – when a major procurement is completed in one country, it is quite natural for there to be lower sales in that market in subsequent periods. It can therefore be difficult to draw general conclusions from comments for individual countries between periods.


Industry/OEM

Industry/OEM showed an increase of 20 percent.

License revenue for the third quarter amounted to SEK 65.5 (65.0) million, which is an increase of 1 percent compared with the same period in the preceding year. Sales accounted for 25 (28) percent of the company's total revenue.

Surgical Science's new agreement from 2025 with its largest customer Intuitive means that the company will move to a fully subscription-based revenue model and that all da Vinci 5 systems (Intuitive's new surgical system) will be equipped with simulation software from Surgical Science. For other robot models, such as the da Vinci Xi, simulation will continue to be offered as an optional feature. The quarter also saw an impact on revenue due to the transition between different generations of surgical systems, with the older generation, where simulation is an option, seeing a decline in the renewal of simulation subscriptions. Compared with the second quarter, this is offset by higher revenue from da Vinci 5.

Adjusted EBIT*



*Excluding acquisition and restructuring costs related to IU in Q1 and Q3 2025

Customers who have just started selling the products from which Surgical Science earns license revenue buy the licenses in packages, which means that this revenue varies more between quarters.

Development revenue, which will generate simulator and license revenue at a later stage, remained strong during the third quarter (SEK 21.9 million compared to SEK 9.5 million in the preceding year). These revenues partly include revenue from robot projects, as well as from the adaptation or development of software linked to the sale of simulators, see below. The quarter includes revenues of USD 0.9 million attributable to the order to supply products to a ministry of defense in a Southeast Asian country, which totals approximately SEK 52 million. This project will be fully recorded under Industry/OEM, while the TraumaVR products sold to hospitals will continue to be recorded under Educational Products. Revenue of USD 0.9 million is expected to be recognized for the fourth quarter.


Sales of simulators to medical device companies for product-specific training amounted to SEK 33.5 (26.1) million. Revenues vary significantly more between quarters than the corresponding sales within Educational Products. These projects have longer lead times and usually include a number of simulators where adaptations for product-specific training of, for example, an OEM company's specific instrument are included.

Service revenue for the installed base, which is mainly linked to longer agreements with specific OEM customers where Surgical Science takes care of the shipping and servicing of their simulators (currently primarily in the US), amounted to SEK 3.7 (3.0) million.

Costs and results

The cost of goods sold amounted to SEK 93.2 (70.8) million corresponding to a gross margin of 65 (69) percent. License revenue made up a lower share of total sales than the corresponding period in the preceding year, which had a negative

Net cash/Accounts receivable



effect on the margin. Currency effects also had a negative impact on the margin of approximately 1.5 percentage points. The lower USD exchange rate has not had an impact on costs, as these inputs were purchased at a higher exchange rate. The proportion of direct sales within Educational Products (mainly in the US) was also lower, and Intelligent Ultrasound has a lower gross margin on its products.

Sales costs amounted to SEK 56.5 (42.6) million corresponding to 21 (18) percent of sales. Starting in the second quarter, additional costs were incurred for customs duties on simulators distributed from production units outside the US. These amounted to approximately SEK 2 million during the quarter. The cost has been passed on to customers. Costs for the quarter also include restructuring costs of SEK 1.5 million attributable to further reductions in the sales workforce in the US as a consequence of the acquisition of Intelligent Ultrasound.

Administration costs amounted to SEK 20.5 (18.0) million corresponding to 8 (8) percent of sales. During the quarter, the merger of Intelligent Ultrasound's US subsidiary with one of Surgical Science's US subsidiaries was completed, resulting in slightly higher legal costs and tax consultancy fees.

Research and development costs amounted to SEK 55.0 (50.6) million, corresponding to 21 (22) percent of sales. Of the development costs, SEK 7.3 (8.7) million has been capitalized as an intangible asset. The costs on this line also vary depending on how much development revenue there is for the quarter, as salaries for the portion of development department staff who have worked on projects that generated development revenue are transferred to the cost of goods sold.

Upon the acquisition of Intelligent Ultrasound, Surgical Science stated that the company estimated that rationalizations and cost savings equivalent to between GBP 1.5 and 2 million on an annual basis would be possible after the acquisition. On an annual basis, cost savings of approximately GBP 2.5 million in relation to the cost structure that existed in the company at the time of the takeover have been implemented, mainly in the form of reduced costs related to the company's previous stock market listing and staff reductions, mainly within sales. Cost savings of just over SEK 6 million are included in the third quarter. Restructuring costs of SEK 1.5 million related to further staff reductions are included in profit for the quarter.


Outstanding warrant programs from 2023 and 2024 were charged against other operating costs for the quarter in the amount of SEK 1.2 (3.4) million. The amount represents a calculation of IFRS2 regarding the parts of the programs attributable to Israel and the US and is allocated across each program's term.

The Annual General Meeting in May 2025 approved another two warrants programs (see further information in Note 4 on pages 19 and 20). The program burdened profit in the quarter by SEK 4.2 million, of which SEK 0.8 million pertains to social security contributions on the Swedish participants' premiums, which were provided free of charge. This cost is included on the relevant line in the income statement, based on the function in which the recipient of the premium is employed. The remainder of the cost, SEK 3.4 million, is attributable to the calculation of IFRS2 and is posted under Other operating costs. The amount comprises the entire IFRS2 cost for the Swedish portion of the programs (SEK 2.6 million), the remainder is attributable to Israel, the US, and the UK and is distributed across the term of the programs until July 2028.

Other items under "Other operating income and operating costs" are mainly attributable to the revaluation of operating assets and operating liabilities in a foreign currency. Currency effects had a negative impact on profits in the amount of SEK 7.2 (negative 2.1) million.

Operating profit for the third quarter amounted to SEK 27.2 million. Adjusted for restructuring costs, operating profit amounted to SEK 28.7 (45.8) million, corresponding to a margin of 11 (20) percent. The operating result for Intelligent Ultrasound was SEK -11.1 million or GBP -0.8 million.

Costs/margin as a percentage of sales, excluding restructuring costs



Depreciation and amortization burdened profit by SEK 20.4 (14.9) million in total. Depreciation and amortization burdened the cost of goods sold by SEK 0.7 (0.5) million, sales costs by SEK 4.5 (4.8) million, administration costs by SEK 7.4 (4.6) million, and research and development costs by SEK 7.8 (5.0) million. Sales costs include amortization of SEK 3.7 (4.0) million on those parts of the company's acquisitions that are classified as customer contracts, while research and development costs include amortization of SEK 1.9 (2.1) million on those parts of the company's acquisitions that are classified as technology. Depreciation attributable to the application of IFRS 16 amounts to SEK 5.9 (3.7) million, this being included in its entirety under administration costs.

Adjusted EBIT amounted to SEK 32.8 million. Adjusted for restructuring costs, adjusted EBIT amounted to SEK 34.3 (51.8) million, corresponding to a margin of 13 (22) percent.

EBITDA amounted to SEK 47.6 million. Adjusted for restructuring costs, EBITDA amounted to SEK 49.1 (60.7) million, corresponding to a margin of 19 (26) percent.

Surgical Science has no loan financing, and net financial items for the quarter mainly consisted of interest income on bank deposits of SEK 2.6 (5.8) million, the revaluation of internal loan liabilities to subsidiaries of SEK 0.4 (3.1) million, and the effect of IFRS 16 of SEK -0.2 (-0.5) million.

Net profit for the quarter amounted to SEK 20.4 (43.0) million. The tax expense for the quarter of SEK 9.7 (10.0) million consists of estimated tax on profit for the period and a change in deferred tax assets. The effective tax rate is higher than in previous periods. The increase is primarily attributable to a larger proportion of loss-making entities within the group, including Intelligent Ultrasound in 2025, which reduces the group's profit before tax and increases the relative effect of tax costs. In addition, certain taxes related to the 2024 fiscal year in the US were reported in the third quarter, as were certain de minimis taxes, which are levied regardless of an entity's profitability.

Cash flow

During the period July to September 2025, cash flow from operating activities amounted to SEK -4.4 million compared to SEK 22.1 million for the corresponding period in 2024. Cash flow from changes in working capital amounted to SEK -44.6 (-32.5) million. Inventories decreased slightly, while accounts receivable increased during the quarter.

Cash flow from investing activities amounted to SEK -10.9 (-12.5) million, mainly comprising investments in development related to the company's software.

Cash flow from financing activities amounted to SEK 4.0 (-3.2) million, where SEK 1.9 (-5.0) million was attributable to changes in lease liabilities in accordance with IFRS 16.

The exchange rate difference in cash and cash equivalents amounted to SEK -1.5 (-7.2) million. Net cash flow for the quarter, including currency effects in liquid assets, was SEK -12.8 (-0.7) million.

First nine months of 2025 (January – September)

Net sales

Net sales for the first nine months of the year amounted to SEK 723.5 (632.5) million, an increase of 14 percent compared with the preceding year. Calculated in local currencies, sales increased by 20 percent.

Net sales for Intelligent Ultrasound are included in sales for the period from February 18, 2025, amounting to SEK 59.2 million. For the period January 1 to February 17, Intelligent Ultrasound's sales amounted to SEK 4.9 million, meaning that total sales for the first nine months of 2025 amounted to SEK 64.1 (85.8) million. All sales are attributable to the Educational Products business area and the ultrasound product group. For comparable units, sales increased by 5 percent.

Of the sales for the period, SEK 372.0 (317.5) million consisted of sales within the Educational Products business area, an increase of 17 percent. Sales within the Industry/OEM business area amounted to SEK 351.5 (315.1) million, an increase of 12 percent.

For revenues by segment, see Note 2 on page 19. License revenue increased by 7 percent and amounted to SEK 208.3 (195.3) million, 29 (31) percent of the company's total revenues.

Net sales rolling 12 months



Costs and results

The cost of goods sold amounted to SEK 244.1 (204.7) million corresponding to a gross margin of 66 (68) percent. License revenue made up a lower share of total sales than the corresponding period in the preceding year, which had a negative effect on the margin. Currency effects, a lower proportion of direct sales in Educational Products (mainly in the US), and the fact that Intelligent Ultrasound has a lower gross margin on its products also had a negative impact on the margin. Price increases have had a positive impact on margins.

Sales costs amounted to SEK 167.4 (125.4) million, corresponding to 23 (20) percent of sales. SEK 5.3 million relates to restructuring costs attributable to the acquisition of Intelligent Ultrasound. Excluding these costs, sales costs amounted to SEK 162.1 million, corresponding to 22 percent of sales.

Administration costs amounted to SEK 87.7 (54.8) million corresponding to 12 (9) percent of sales. These costs include Surgical Science's acquisition costs of SEK 22.6 million related to Intelligent Ultrasound. These costs consisted mainly of legal advice in the complicated process of acquiring a listed company in the UK through a court process. Excluding these costs, administration costs amounted to SEK 65.1 million, corresponding to 8 percent of sales.

Research and development costs amounted to SEK 162.4 (144.5) million, corresponding to 22 (23) percent of sales. During the first nine months of the year, development costs of SEK 27.3 (28.1) million were capitalized as an intangible asset.

Outstanding warrants programs have been charged to other operating costs for the first nine months in the amount of SEK 7.7 (6.4) million. Other items under "Other operating income and operating costs" are mainly attributable to the revaluation of operating assets and operating liabilities in a foreign currency, amounting to SEK -30.2 (5.5) million. The first nine months of the year also include non-recurring income (GBP 0.4 million or SEK 5.8 million) in Intelligent Ultrasound, for a replacement program of older products. The cost of these is found on the same line (GBP -0.2 million or SEK -2.9 million).

Operating profit for the first nine months of the year amounted to SEK 28.7 (105.2) million, corresponding to an operating margin of 4 (17) percent. Adjusted for acquisition and restructuring costs, operating profit amounted to SEK 56.6 million, corresponding to a margin of 8 percent. Operating result consolidated for Intelligent Ultrasound is GBP -1.5 million or SEK -19.3 million. The company's total operating result for the first nine months of the year, including result before the acquisition on February 18, was GBP -4.0 million or SEK -52.7 million. Operating result for the period before the acquisition includes Intelligent Ultrasound's costs for advisors in connection with the acquisition, amounting to GBP 1.2 million or SEK 16.4 million.

With regard to the surplus value in the group attributable to the acquisition of Intelligent Ultrasound, amounting to SEK 16.6 million, no allocation has been made to amortizable assets and, consequently, no amortization is made on such surplus values.

Depreciation and amortization burdened profit by SEK 59.4 (44.2) million in total. Depreciation and amortization burdened the cost of goods sold by SEK 1.9 (1.5) million, sales costs by SEK 14.0 (14.3) million, administration costs by SEK 21.1 (13.8)

million, and research and development costs by SEK 22.5 (14.6) million. Sales costs include amortization of SEK 11.5 (12.0) million on those parts of the company's acquisitions that are classified as customer contracts, while research and development costs include amortization of SEK 5.9 (6.2) million on those parts of the company's acquisitions that are classified as technology. Depreciation attributable to the application of IFRS 16 amounts to SEK 17.0 (11.1) million, this being included in its entirety under administration costs.

Adjusted EBIT amounted to SEK 46.1 million. Adjusted for acquisition and restructuring costs, adjusted EBIT amounted to SEK 74.0 (123.4) million, corresponding to a margin of 10 (20) percent.

EBITDA amounted to SEK 88.2 million. Adjusted for acquisition and restructuring costs, EBITDA amounted to SEK 116.1 (149.4) million, corresponding to a margin of 16 (24) percent.

Net financial items amounted to SEK 28.9 (13.5) million and consisted mainly of interest income on bank balances of SEK 12.6 (16.6) million. Other items include interest costs on short-term loans of SEK -2.5 (-) million, currency effects from a short-term loan in connection with the acquisition of Intelligent Ultrasound and the revaluation of intra-group loans of SEK 20.8 (-0.2) million, and the effect of IFRS 16 of SEK -2.0 (-1.6) million.

Net profit for the period amounted to SEK 33.6 (95.4) million. The tax expense for the period of SEK 24.1 (23.3) million consists of estimated tax on profit for the period and a change in deferred tax assets. The acquisition costs for Intelligent Ultrasound are not tax-deductible. For 2025, there are tax-loss carry-forwards in the US attributable to Mimic Technologies, and in the UK attributable to Intelligent Ultrasound.

Cash flow

During the first nine months of 2025, cash flow from operating activities amounted to SEK 6.9 million compared to SEK 80.6 million for the corresponding period in 2024. Cash flow from changes in working capital amounted to SEK -58.7 (-63.7) million. Both inventory and accounts receivable have increased.

Cash flow from investing activities amounted to SEK -119.1 (-35.4) million. SEK -84.9 million is attributable to the acquisition of Intelligent Ultrasound, see note 5 on pages 20 and 21. The remaining part consists mainly of investments in development related to the company's software.

Cash flow from financing activities amounted to SEK -234.0 (-12.4) million, where SEK 3.2 (-6.4) million was attributable to changes in lease liabilities in accordance with IFRS 16. In connection with the offer to acquire Intelligent Ultrasound in December 2024, a short-term loan of GBP 17 million was taken

out. This was repaid during the first quarter, which negatively impacted cash flow from financing activities by SEK 235.4 million.

Net cash flow, including currency effects in liquid assets, was SEK -370.8 (32.0) million for the first nine months of the year.

General comments on the accounts

Surgical Science's operations are structured into two business areas; Educational Products and Industry/OEM.

Sales within Educational Products consist of sales of the company's proprietary simulators (hardware and software) to the hospital market, as well as of service revenue related to the installed base of these simulators. The revenue from simulators is mainly of a one-off nature, while service revenue recurs throughout the term of each contract.

Sales within Industry/OEM consist of license revenue from the company's software and are primarily attributable to the robotic surgery area. Revenue consists partly of revenue linked to each robot's serial number (fixed for each unit) and partly of recurring revenue linked to the installed base or use of the software, for example. Development revenue is also included, which is obtained when Surgical Science works to adapt the company's software to the customer's hardware platform. The area also includes the sale of simulators to OEM customers, primarily in the vascular area but also in ultrasound and laparoscopy, for example, as well as service revenue related to the installed base of these simulators.

Pages 16 to 18 of Surgical Science's annual report for 2024 provides a detailed account of the company's business model and the various revenue streams. Pages 19 and 20 provide a general description of the customer journey with the robotics companies.

The gross margin is affected by the distribution of revenues, as the different revenue streams, "proprietary simulators containing hardware", "service revenues", "development revenues" and "license revenues", have different gross margins. A higher share of license revenue has a positive impact on the gross margin.

Surgical Science applies a functionally arranged income statement in which the gross margin also includes the salaries of employees working with production, quality control and support, in addition to direct materials and spare parts. In addition, the salaries of development department employees working on development revenue-generating projects are included. Shared costs, such as premises and IT, are distributed in accordance with an allocation template for all the different functions.

Other operating income and operating costs consist predominantly of exchange rate fluctuations on operating assets and operating liabilities in foreign currencies.

As Surgical Science does not have any loan financing (except for a short-term loan of GBP 17 million between the fourth quarter of 2024 and the first quarter of 2025, related to the acquisition of Intelligent Ultrasound), net financial items consist mainly of interest on bank balances, revaluation of internal loan receivables/payables to subsidiaries, and the impact of IFRS 16.

Loss carry-forwards remained in the US for 2024, attributable to Mimic Technologies. For 2025, there are tax-loss carry-forwards in the US attributable to Mimic Technologies, and in the UK attributable to Intelligent Ultrasound.

Impact of US tariffs

For 2024, Surgical Science's total sales (for both business areas, including Intelligent Ultrasound) of simulators to the US were approximately SEK 250 million. These sales are directly affected by tariffs. With a 15 percent tariff level, Surgical Science estimates the impact to be around SEK 15 million per year. The ambition is to reflect this cost in the price of the products as much as possible, and the possibility of doing so is considered good. For the remaining part of the business, there are indirect effects that are currently difficult to predict.

Exposure to foreign currency

Surgical Science is mainly exposed to USD, ILS, EUR, and GBP. Exposure varies depending on how large a proportion of the revenues and costs are made up of these currencies in relation to the company's total revenues and costs. The company has not hedged its flows by way of hedging agreements.

In 2025, the USD has weakened, which has had a major impact on Surgical Science's sales and earnings. Work is underway to invoice customers in EUR instead of USD wherever possible.

For the full year 2024, Surgical Science's revenues had the following approximate distribution across different currencies (pro forma including Intelligent Ultrasound): USD 79 (82) percent, EUR 14 (16) percent, SEK 2 (2) percent, GBP 4 (0) percent, other (e.g. ILS) 1 (0) percent.

Costs for the full year 2024 had the following approximate distribution across different currencies (pro forma including Intelligent Ultrasound): USD 29 (28) percent, ILS 41 (51) percent, SEK 15 (17) percent, GBP 11 (0) percent, other (e.g. EUR) 4 (4) percent.

Financial position

As at September 30, 2025, the group's cash and cash equivalents amounted to SEK 597.4 million, equity to SEK 4,299.9 million, and the equity/assets ratio was 91 percent. As at September 30, 2024, the group's cash and cash equivalents amounted to SEK 666.3 million, equity to SEK 4,449.1 million, and the equity/assets ratio was 93 percent. As at September 30, 2025, equity per share amounted to SEK 84.27 (87.19).

Parent company

The parent company, Surgical Science Sweden AB, holds shares in subsidiaries and the portion of Surgical Sciences' Swedish operations that are primarily conducted in Gothenburg. Several group-wide functions are also organized within the parent company. Due to internal transactions between the various group companies, it is not possible to draw general conclusions from the parent company's figures regarding sales and operating costs.

During the quarter, USD 10 million was received as dividends from the US subsidiary, which were converted to SEK.

Outlook

Surgical Science's strategy is to have two separate business areas. The focus of Educational Products is on customers in education and training, who use the company's proprietary simulators to increase patient safety through effective, generic training, the results of which can be measured objectively. Customers have validated the simulators over many years by way of clinical studies. The other business area, Industry/OEM, primarily makes use of Surgical Science's software resources, which enable medical device companies to integrate product-specific simulation into their clinical products. This makes it possible to generate a return on Surgical Science's development work, which has been ongoing for 25 years. The company perceives the strongest future growth to be in this area. In robotic surgery, the principal business model involves a development fee for customization/integration with the customer's products and then a software license for each unit or based on the installed base or on usage. Surgical Science retains full copyright over its product.

Underlying growth in the market for medical simulation is favorable. The largest market for medical simulation is the US, followed by Europe and Asia. Over the next few years, growth is expected to be strongest in countries where driving forces include economic development, an increased focus on patient safety, and a large population, such as China and India. The market for robot-assisted surgery is expected to grow quicker than other parts of the market.

The overarching objectives for Surgical Science in 2025 are to:

- Ensure successful integration of Intelligent Ultrasound and safeguard planned synergies.
- Establish broader partnerships and increase the number of customers in the Medical Device Simulation segment of Industry/OEM.
- Grow organic sales in Educational Products by 10 to 15 percent.
- Continue to expand the product portfolio through further product launches.
- Improve gross margin in Educational Products, including Intelligent Ultrasound, by streamlining the product portfolio and increasing average selling price.
- Ensure a high level of employee commitment by continuing to build and maintain the culture and the company's core values.
- Improve internal efficiency and the level of automation to respond more quickly and cost-effectively to increased customer demand and to handle more customers and business.
- Be prepared to make further acquisitions when the time is right.

Surgical Science has an organization where a sizable portion of its employees are global leaders in software development for medical simulation. This gives the company the capacity to work with the development of the core technology for future simulation, with on-time delivery of adaptations of simulation software to customers in Industry/OEM, and to continue to launch new applications for its proprietary products within Educational Products. To remain the world leader in realistic real-time simulations of medical procedures, improving the core technology is critical. In 2025, Surgical Science is continuing to invest more than ever in this area.

The company in brief

Operations

Surgical Science was founded in 1999 and works with simulation technologies. The foundation of the company is its proprietary software and hardware for simulating interactions between instruments and anatomy. Based on its proprietary technology, Surgical Science develops and sells turnkey simulation systems used to train surgeons and other medical specialists. The operations are conducted within the framework of the Educational Products business area. Since 2017, Surgical Science has also worked with simulation solutions for medical device companies that develop surgical instruments for clinical applications (such as robot-assisted surgery) – this work is conducted within the Industry/OEM business area.

Mission and vision

Surgical Science's overall purpose is to improve patient safety and outcomes in healthcare through validated, customized

medical simulation training. The vision is that all patients who are on their way to the operating room should feel confident that their surgeon has been trained and objectively certified in a safe, simulated environment before the procedure commences.

Financial targets

During the first quarter of 2025, Surgical Science revised its financial targets. Developments primarily in the Robotics segment, combined with the current trading uncertainty, where direct and indirect effects are difficult to predict, have led the company's board and management to adjust the sales target for 2026 to SEK 1,400 million from the previous SEK 1,500 million.

The lower share of license revenue relative to total revenue, together with increased investments in areas that also include hardware, has resulted in the adjusted EBIT target for 2026 being revised to 25-30 percent, from the previous 40 percent.

Surgical Science is currently conducting a strategy review to capitalize on and realize the growth opportunities that the company sees in the market going forward. Updated financial targets will be announced on the morning of December 8, 2025.

Strategy

Surgical Science will continue to develop its proprietary educational products to be the obvious choices for customers in a world where training and certification are mandatory. From the outset, Surgical Science has worked closely with leading university hospitals in the development of the company's products. Surgical Science's simulators have also been validated in a number of published studies demonstrating that the knowledge acquired by the surgeon by way of training with the company's products also transfers to the actual operating room. Surgical Science advocates mandatory simulations in surgeon training and for the certification of future surgeons before performing their first operation on a human patient.

Besides developing proprietary products, a strategic priority is to work with simulation solutions for medical device companies that develop instruments for clinical use. As a result of the more than 25 years of research and development behind the world's most advanced, computer-based simulations for the training of surgeons and other medical specialists in a wide range of areas, Surgical Science's software resources can be applied beyond the proprietary products.

One of the macro trends in healthcare driving this development is digitalization, which allows simulation software to be applied directly in medical device products without separate hardware. Another macro trend is increasing patient safety awareness, especially with regard to new technologies. This is

evident in, for example, regulatory authorities' requirements for verified training solutions for surgeons when granting approval for the clinical use of new surgical robots, for instance.

Other information

Organization and personnel

At the end of the period, there were 328 (270) employees, of whom 90 (74) were women and 238 (196) were men. Of these, 70 (61) were employed in Sweden, 152 (139) in Israel, 54 (54) in the US, 33 (1) in the UK, and the remaining 19 (16) mainly in Germany and China.

Information on transactions with related parties

In addition to his board fees, board member Thomas Eklund received consultancy fees of SEK 248 thousand in the second quarter for his work on the company's strategies during 2025.

No other transactions materially impacting the company's profit or financial position were conducted with related parties during the quarter or the period.

Risk management

Surgical Science works on an ongoing basis to identify, assess and manage risks in various systems and processes. Risk analyses of day-to-day operations are performed on an ongoing basis and in connection with major activities.

The most significant strategic and operational risks affecting Surgical Science's operations and industry are described on pages 67 and 68 of the company's 2024 annual report. The principal risks and uncertainties include IP, market risks, competitors and technological development, industrial partnerships, employees, acquisitions and access to capital. To all intents and purposes, the risks reported by the company and outlined in the annual report, are judged to have remained unchanged.

Seasonal effects

Surgical Science's sales within the Educational Products business area can fluctuate between quarters, with the fourth quarter of the year usually being the strongest. This is because many major hospitals use the calendar year as their budget year and hold off on purchases until they can see what funds remain in the budget towards the end of the year.

Also in the Industry/OEM business area, the fourth quarter usually generates more sales than other quarters, with license revenues from customers increasing for the same reason as for Educational Products. This effect is less pronounced for Industry/OEM, however, as clinical products in the area of robotic surgery, for example, are less dependent on there being remaining budget funds towards the end of the year.

Events after the balance sheet date

There have been no significant events to report following the end of the period.

Assurance

The board and CEO provide their assurance that this interim report provides a fair overview of the company's operations, position, and earnings and describes any significant risks and uncertainties that the company may face.

Gothenburg, November 13, 2025

Board of directors

This report has not been subject to review by the company's auditors.

Financial reports:

Interim reports and other financial reports are available at www.surgicalscience.com.

The following reports are planned for release:

Year-end report 2025: Thursday, February 19, 2026
Interim report January–March 2026: Wednesday, May 20
Interim report January–June 2026: Wednesday, August 19
Interim report January–September 2026: Thursday, November 12
Year-end report 2026: Tuesday, February 23, 2027

Other dates

Capital Markets Day 2025: Monday, December 8
Annual general meeting 2026: Thursday, May 21

Stock market and Certified Adviser:

Shares in Surgical Science Sweden AB (publ) have been traded on Nasdaq First North Growth Market since June 19, 2017. The company's Certified Adviser is DNB Carnegie Investment Bank AB.

Please address any questions to:

Tom Englund, CEO
Phone: +46 (0)70 916 16 81
tom.englund@surgicalscience.com

Anna Ahlberg, CFO
Phone: +46 (0)70 855 38 35
anna.ahlberg@surgicalscience.com

This is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons above on November 13, 2025, at 7:30 a.m. (CET).

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Condensed consolidated income statements

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Net sales	723,490	632,537	263,641	231,828	884,087
Cost of goods sold	-244,067	-204,716	-93,211	-70,816	-286,189
Gross profit	479,423	427,821	170,430	161,012	597,897
Sales costs	-167,372	-125,362	-56,466	-42,617	-175,260
Administration costs	-87,729	-54,782	-20,484	-18,040	-77,119
Research and development costs	-162,357	-144,455	-55,027	-50,575	-196,110
Other operating income and costs	-33,224	1,969	-11,204	-3,995	-5,087
Operating profit	28,741	105,192	27,249	45,786	144,320
Financial income and costs	28,902	13,477	2,900	7,239	13,773
Profit after financial items	57,643	118,670	30,148	53,025	158,093
Taxes	-24,080	-23,287	-9,746	-10,002	-26,446
Net profit	33,563	95,382	20,402	43,023	131,646
Attributable to					
Parent company shareholders	33,563	95,382	20,402	43,023	131,646
Earnings per share, SEK	0.66	1.87	0.40	0.84	2.58
Earnings per share, SEK*	0.66	1.87	0.40	0.84	2.58
Amortization of intangible assets	-34,047	-27,596	-11,517	-9,172	-36,892
Depreciation of tangible assets	-25,375	-16,593	-8,852	-5,716	-23,623

* After dilution. See Note 4 for information regarding warrants programs.

Consolidated statement of income and other comprehensive income

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Net profit	33,563	95,382	20,402	43,023	131,646
Other comprehensive income					
<i>Items that have been or can be reclassified to net profit</i>					
Translation differences on translation of foreign operations	-569,991	2,854	-32,498	-190,872	344,546
Total other comprehensive income	-569,991	2,854	-32,498	-188,739	344,546
Comprehensive income	-536,428	98,236	-12,096	-147,849	476,192
Comprehensive income attributable to					
Parent company shareholders	-536,428	98,236	-12,096	-147,849	476,192

Condensed consolidated statement of financial position

SEK thousands	Sep 30, 2025	Sep 30, 2024	Dec 31, 2024
ASSETS			
Non-current assets			
Capitalized expenditure for product development	110,281	85,204	98,457
Patents, trademarks, and concessions	52,479	56,828	61,759
Customer contracts	43,287	90,471	92,445
Technology	75,702	54,347	57,055
Goodwill	3,143,382	3,339,163	3,615,848
Other intangible fixed assets	24,059	2,215	2,189
Tangible fixed assets	110,962	69,699	101,534
Deferred tax assets	14,150	14,702	16,331
Other financial fixed assets	8,420	7,257	8,049
Total non-current assets	3,582,722	3,719,886	4,053,666
Current assets			
Inventories	204,532	174,235	179,583
Accounts receivable	144,076	130,839	136,702
Other current receivables	67,555	31,058	43,652
Prepaid expenses and accrued income	107,251	80,097	97,914
Cash and cash equivalents	597,387	666,325	968,155
Total current assets	1,120,800	1,082,555	1,426,007
TOTAL ASSETS	4,703,522	4,802,441	5,479,673
EQUITY AND LIABILITIES			
Equity attributable to parent company shareholders	4,299,940	4,449,145	4,828,639
Non-current liabilities	135,308	109,471	138,313
Liabilities to credit institutions	1,625	–	235,408
Other current liabilities	266,260	243,825	277,314
Total liabilities	403,582	353,296	651,035
TOTAL EQUITY AND LIABILITIES	4,703,522	4,802,441	5,479,673

Consolidated changes in equity

SEK thousands	Attributable to parent company shareholders				Total equity
	Share capital	Other capital contributions	Provisions	Profit and loss carried forward, incl. profit for the period	
Opening balance January 1, 2024	2,551	3,398,121	436,777	507,763	4,345,212
Profit for the period Jan–Sep				95,382	95,382
Other comprehensive income for the period			2,854		2,854
Warrants program IFRS 2			5,696		5,696
Closing balance September 30, 2024	2,551	3,398,121	445,327	603,145	4,449,145
Profit for the period Oct–Dec				36,264	36,264
Other comprehensive income for the period			341,692		341,692
Warrants program IFRS 2			1,538		1,538
Closing balance December 31, 2024	2,551	3,398,121	788,557	639,409	4,828,639
Opening balance January 1, 2025	2,551	3,398,121	788,557	639,409	4,828,639
Profit for the period Jan–Sep				33,563	33,563
Other comprehensive income for the period			-569,991		-569,991
Warrants program IFRS 2			7,729		7,729
Closing balance September 30, 2025	2,551	3,398,121	226,295	672,972	4,299,940

Condensed consolidated cash flow statements

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Operating activities					
Profit before financial items	28,741	105,192	27,191	45,786	144,320
Adjustment for non-cash items, etc.	80,886	43,859	19,845	19,195	67,711
Interest paid/received	7,450	11,697	1,598	3,046	18,768
Tax paid	-51,493	-16,510	-8,449	-13,436	-27,686
Cash flow from operating activities before changes in working capital	65,584	144,238	40,197	54,591	203,113
Changes in working capital					
Increase (-)/Decrease (+) in inventories	-15,665	-23,622	-176	-3,541	-11,556
Increase (-)/Decrease (+) in operating receivables	-51,496	-45,864	-36,243	-22,168	-20,238
Increase (+)/Decrease (-) in operating liabilities	8,487	5,805	-8,134	-6,793	-34,094
Cash flow from changes in working capital	-58,674	-63,682	-44,553	-32,502	-65,888
Cash flow from operating activities	6,909	80,556	-4,368	22,089	137,225
Investing activities					
Investments in tangible fixed assets	-5,441	-5,635	-2,305	-2,902	-6,104
Investments in intangible fixed assets	-28,774	-29,768	-8,618	-9,623	-41,426
Investment in business	-84,914	–	–	–	–
Cash flow from investing activities	-119,129	-35,404	-10,923	-12,525	-47,530
Financing activities					
Change in non-current liabilities	-1,824	-6,013	2,059	1,851	-5,525
Change in liabilities to credit institutions	-235,408	–	–	–	235,408
Change in lease liabilities	3,215	-6,375	1,926	-5,014	-2,230
Cash flow from financing activities	-234,015	-12,387	3,984	-3,163	227,653
Cash flow for the period	-346,235	32,767	-11,295	6,402	317,348
Opening cash and cash equivalents	968,155	634,366	610,214	667,074	634,366
Exchange-rate difference in cash and cash equivalents	-24,533	-806	-1,532	-7,151	16,441
Closing cash and cash equivalents	597,387	666,325	597,387	666,325	968,155

Key figures, group

	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Net sales growth, %	14.4	-3.5	13.7	10.3	0.1
Gross margin, %	66.3	67.6	64.6	69.5	67.6
EBITDA margin, %	12.2	23.6	18.0	26.2	23.2
Operating margin, %	4.0	16.6	10.3	19.7	16.3
Profit margin, %	4.6	15.1	7.7	18.6	14.9
Equity/assets ratio, %	91.4	92.6	91.4	92.6	88.1
Shares outstanding at end of period	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Equity per share, SEK	84.27	87.19	84.27	87.19	94.63
Equity per share, SEK*	84.27	87.19	84.27	87.19	94.63
Dividend per share, SEK	0.00	0.00	0.00	0.00	0.00
Share price on the balance sheet date, SEK	87.95	126.90	87.95	126.90	155.90
Average number of employees	309	254	320	254	256

* After dilution. See Note 4 for information regarding warrants programs. | See page 22 for definitions of key figures.

Consolidated income statements by quarter

SEK thousands	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024	Jul-Sep 2024	Apr-Jun 2024	Jan-Mar 2024	Oct-Dec 2023
Net sales	263,641	209,157	250,691	251,549	231,828	212,466	188,243	227,293
Cost of goods sold	-93,211	-72,763	-78,092	-81,474	-70,816	-68,982	-64,918	-64,864
Gross profit	170,430	136,394	172,599	170,076	161,012	143,484	123,325	162,429
Sales costs	-56,466	-57,783	-53,122	-49,898	-42,617	-42,290	-40,456	-42,502
Administration costs	-20,484	-23,493	-43,752	-22,338	-18,040	-20,998	-15,744	-19,750
Research and development costs	-55,027	-52,123	-55,206	-51,656	-50,575	-48,841	-45,039	-46,247
Other operating income and costs	-11,204	-25,382	3,419	-7,056	-3,995	2,075	3,890	-16,275
Operating profit/loss (-)	27,249	-22,388	23,938	39,128	45,786	33,430	25,976	37,655
Financial income and costs	2,900	3,670	22,273	295	7,239	4,376	1,862	80,784
Profit after financial items	30,148	-18,718	46,211	39,423	53,025	37,806	27,838	118,439
Taxes	-9,746	-1,359	-12,974	-3,159	-10,002	-9,238	-4,046	-20,478
Net profit/loss (-)	20,402	-20,077	33,237	36,264	43,023	28,568	23,792	97,962
Attributable to								
Parent company shareholders	20,402	-20,077	33,237	36,264	43,023	28,568	23,792	97,962
Earnings per share, SEK	0.40	-0.39	0.65	0.71	0.84	0.56	0.47	1.92
Earnings per share, SEK*	0.40	-0.39	0.65	0.71	0.84	0.56	0.47	1.92
Average shares outstanding	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,044,111

* After dilution. See Note 4 for information regarding warrants programs.

Parent company income statements

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Net sales	234,954	82,471	89,799	37,354	126,574
Cost of goods sold	-108,584	-32,292	-34,685	-16,538	-55,459
Gross profit	126,370	50,179	55,114	20,816	71,115
Sales costs	-15,970	-12,667	-5,198	-4,003	-18,915
Administration costs	-16,959	-14,469	-5,153	-5,112	-21,441
Research and development costs	-18,968	-21,017	-5,740	-5,618	-28,960
Other operating income and costs	-11,729	-4,666	-6,708	-4,822	-5,257
Operating profit	62,744	-2,640	32,315	1,262	-3,457
Dividends from subsidiaries	582,715	–	93,628	–	–
Other financial income and costs	26,148	12,295	2,532	6,475	7,800
Profit after financial items	671,607	9,655	128,475	7,736	4,343
Appropriations (group contributions)	–	–	–	–	63,557
Taxes	-18,312	-1,989	-7,179	-1,594	-14,437
Net profit	653,295	7,666	121,297	6,143	53,464
Amortization of intangible assets	-7,460	-6,006	-2,487	-1,970	-7,978
Depreciation of tangible assets	-576	-738	-190	-243	-957

Because the parent company has no items to report under Other comprehensive income, no statement of comprehensive income has been prepared.

Condensed parent company balance sheets

SEK thousands	Sep 30, 2025	Sep 30, 2024	Dec 31, 2024
ASSETS			
Non-current assets			
Capitalized expenditure for product development	29,341	30,028	30,664
Other intangible fixed assets	1,182	1,125	1,075
Tangible fixed assets	1,167	1,906	1,687
Participations in group companies	3,764,559	3,131,505	3,131,505
Total non-current assets	3,796,249	3,164,565	3,164,931
Current assets			
Inventories	7,951	6,041	6,659
Accounts receivable	19,045	18,457	27,761
Current receivables from group companies	86,985	18,748	71,845
Other current receivables	15,171	1,474	1,940
Prepaid expenses and accrued income	91,101	9,033	14,089
Cash and bank position	403,424	418,120	659,075
Total current assets	623,677	471,874	781,370
TOTAL ASSETS	4,419,927	3,636,438	3,946,300
EQUITY AND LIABILITIES			
Equity	4,228,786	3,520,426	3,567,762
Liabilities to credit institutions	1,625	–	235,408
Current receivables from group companies	110,783	77,878	78,112
Other current liabilities	78,733	38,135	65,019
Total liabilities	191,141	116,012	378,539
TOTAL EQUITY AND LIABILITIES	4,419,927	3,636,438	3,946,300

Note 1. Accounting principles

As regards the group, this interim report has been prepared in accordance with the Annual Accounts Act and IAS 34 Interim Financial Reporting and, as regards the parent company, in accordance with the Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. Unless stated otherwise below, the accounting principles applied for the group and the parent company are the same as those applied in preparing the most recent annual report.

Disclosures in accordance with IAS 34.16A appear not only in the financial statements and the accompanying notes, but also in other parts of the interim report.

Note 2. Group operating segments

Revenue by business area and revenue stream

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Educational Products	371,996	317,452	138,969	128,277	442,496
- Simulators, hardware and software	314,163	257,253	120,071	109,055	364,345
- Service and support revenue	57,834	60,199	18,898	19,222	78,151
Industry/OEM	351,493	315,085	124,672	103,551	441,591
- Simulators, hardware and software	79,084	84,210	33,533	26,139	126,716
- Service and support revenue	9,419	9,127	3,664	2,956	12,095
- License revenue	208,279	195,293	65,533	64,961	271,657
- Development revenue	54,711	26,455	21,942	9,495	31,123
Net sales	723,490	632,537	263,641	231,828	884,087

Revenue by business area and geographic area

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Educational Products	371,996	317,452	138,969	128,277	442,496
- Europe	101,185	58,919	43,554	29,821	92,900
- North and South America	185,013	164,293	61,024	56,111	207,011
- Asia	66,955	72,652	29,505	30,957	111,149
- Other	18,843	21,588	4,886	11,388	31,436
Industry/OEM	351,493	315,085	124,672	103,551	441,591
- Europe	40,642	33,513	13,866	18,371	59,893
- North and South America	271,365	259,551	91,852	76,639	355,988
- Asia	33,724	18,274	15,216	7,626	21,140
- Other	5,762	3,747	3,738	915	4,570
Net sales	723,490	632,537	263,641	231,828	884,087

Revenue by product group

SEK thousands	January – September		July – September		Full year
	2025	2024	2025	2024	2024
Robotics	258,960	238,046	89,202	77,717	336,593
Vascular surgery	108,056	110,279	50,796	38,082	153,946
Laparoscopy	69,862	82,452	24,718	41,418	124,494
Endoscopy	78,309	86,532	25,963	35,796	112,345
Ultrasound	123,595	62,238	45,368	18,633	89,201
Other	84,762	52,990	27,594	20,183	67,507
Net sales	723,490	632,537	263,641	231,828	884,087

Note 3. Financial instruments

SEK thousands	Sep 30, 2025	Sep 30, 2024	Dec 31, 2024
Financial assets	755,929	811,742	1,119,923
Financial liabilities	232,735	173,446	445,069

The group's financial assets and liabilities are valued at amortized cost, with the exception of the deferred contingent consideration recognized as a liability and measured at fair value. The carrying amount is considered to be a reasonable approximation of the fair value of the group's assets and liabilities in the balance sheet.

Note 4. Warrants programs

Warrants 2022_25

Surgical Science's annual general meeting on May 12, 2022 resolved to establish an incentive program for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 175.70 during the period June 10 to July 10, 2025. The company subsidizes the warrants program so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 28.74 per warrant.

During the subscription period, the company's average share price was below the set exercise price, which meant that no options were exercised. All 200,000 warrants thus expired without value. As a result, both the number of shares and the share capital remained unchanged, and there was no dilution of existing shareholders' ownership interests or voting rights.

Warrants 2023_26

Surgical Science's annual general meeting on May 17, 2023 resolved to establish an incentive program for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 294.70 during the period June 15 to July 15, 2026. The company subsidizes the warrants program so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 36.43 per warrant.

During the current period, the average share price for the period, the closing price on the balance sheet date, and the average share price for the rolling 12-month period were all below the exercise price for the warrant program, whereby the program did not entail any dilution effect. Fully exercised, the incentive program will increase Surgical Science's share capital by SEK 13,000 and the number of shares by 260,000, corresponding to the dilution of the total number of shares and votes by about 0.5 percent.

Incentive program costs

Preliminarily, the incentive program is estimated to entail social security contributions of SEK 0.5 million, as well as costs of SEK 9.0 million in accordance with the accounting rules under IFRS2. For the first nine months of 2025, the program has impacted profits negatively by SEK 1.9 (1.9) million. The amount comprises the IFRS2 cost attributable to Israel and the US and is distributed across the term of the program until July 2026.

Warrants 2024_27

Surgical Science's annual general meeting on May 16, 2024 resolved to establish two incentive programs for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 170.50 during the period June 14 to July 14, 2027. The company subsidizes the warrants programs so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 33.31 per warrant.

During the current period, the average share price for the period, the closing price on the balance sheet date, and the average share price for the rolling 12-month period were all below the exercise price for the warrant program,

whereby the program did not entail any dilution effect. Fully exercised, the two incentive programs will increase Surgical Science's share capital by SEK 16,400 and the number of shares by 328,000, corresponding to the dilution of the total number of shares and votes by about 0.6 percent.

Incentive program costs

Preliminarily, the incentive programs are estimated to entail social security contributions of SEK 1.3 million, as well as costs of SEK 10.4 million in accordance with the accounting rules under IFRS2. For the first nine months of 2025, the program has impacted profits negatively by SEK 1.8 (3.4) million. The amount comprises the IFRS2 cost attributable to Israel and the US and is distributed across the term of the program until July 2027.

Warrants 2025_28

Surgical Science's annual general meeting on May 15, 2025 resolved to establish two incentive programs for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 173.90 during the period June 14 to July 14, 2028. The company subsidizes the warrants programs so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 36.42 per warrant.

Fully exercised, the two incentive programs will increase Surgical Science's share capital by SEK 20,100 and the number of shares by 402,000, corresponding to the dilution of the total number of shares and votes by about 0.8 percent. As at the balance sheet date of September 30, 2025, the warrants programs entailed no dilution.

Incentive program costs

Preliminarily, the incentive programs are estimated to entail social security contributions of SEK 1.1 million, as well as costs of SEK 13.5 million in accordance with the accounting rules under IFRS2. For the first nine months of 2025, the programs burdened profit by SEK 4.2 (-) million, of which SEK 0.8 million pertains to social security contributions on the Swedish participants' premiums, which were provided free of charge. The remainder of the cost, SEK 3.4 million, is attributable to the calculation of IFRS2. The amount comprises the entire IFRS2 cost for the Swedish portion of the programs (SEK 2.6 million), the remainder is attributable to Israel, the US, and the UK and is distributed across the term of the programs until July 2028.

Programs 2023_26, 2024_27, and 2025_28

The board is authorized to adjust the program in response to organizational changes and to specific rules or market conditions in other countries. Most of the company's employees are employed outside Sweden, in the US and in Israel. For tax reasons, these employees are contractually entitled to subscribe for shares (Non-Qualified Stock Options) rather than warrants. In accordance with generally accepted practices in these markets, participants receive these shares free of charge.

Note 5. Acquisition of business

On December 19, 2024, Surgical Science announced a recommended offer to acquire 100 percent of the issued share capital of Intelligent Ultrasound Group plc (IU), a UK-based ultrasound simulation company listed on the Alternative Investment Market of the London Stock Exchange. The acquisition, which was completed on February 18, 2025, amounted to approximately SEK 630 million on a fully diluted basis, corresponding to a value of approximately SEK 65 million on a cash and debt-free basis. The valuation implies a sales multiple (2023) of approximately 0.5 times Intelligent Ultrasound's sales.

Rationale for the acquisition

- Strategic portfolio enhancement: Intelligent Ultrasound offers proprietary ultrasound simulation solutions for several medical fields that complement Surgical Science's offering in this area.
- Innovation-led expansion: Intelligent Ultrasound will become part of Surgical Science's development organization, providing volumetric ultrasound technology.
- Larger commercial footprint in the UK and US: Direct sales are established

- in the UK market, while the commercial footprint in the US is expanded.
- Economies of scale: With increased scale, Surgical Science can generate greater customer value by effectively leveraging shared functions and sales channels.
- Attractive price: Following the sale of its AI business to GE Healthcare, Surgical Science is acquiring Intelligent Ultrasound at a sales multiple of approximately 0.5, more than doubling the company's sales in ultrasound in 2024.

The purchase consideration, the fair value of the acquired net assets and goodwill are as follows:

SEK thousand	
Cash payment	610,449
Fair value of acquired net assets	-593,857
Total goodwill	16,592

Goodwill is attributable to the acquired workforce and synergies in the form of cost savings that do not meet the criteria for separate recognition.

(a) Consideration

The purchase consideration amounted to GBP 45.2 million/SEK 610 million after full dilution on a cash and debt-free basis. There is no conditional purchase consideration.

(b) The assets and liabilities recognized as a result of the acquisition are shown below:

Carrying amount of identifiable assets and liabilities at the time of acquisition

SEK thousand	Recognized value in Intelligent Ultrasound as at February 18, 2025	Fair value adjustment	Fair value reported in the group
Intangible fixed assets	27,898		27,898
Tangible fixed assets	11,285		11,285
Non-current receivables	820		820
Inventories	22,399		22,399
Current receivables	24,122		24,122
Prepaid expenses and accrued income	40,412		40,412
Cash and cash equivalents	525,535		525,535
Non-interest-bearing liabilities	-9,030		-9,030
Accounts payable	-13,312		-13,312
Other current liabilities	-27,214		-27,214
Prepaid income and accrued expenses	-9,058		-9,058
Net identifiable assets and liabilities	593,857		593,857

Acquisition costs

Acquisition-related costs of SEK 22.6 million are included in the group's administration costs in the income statement and in operating activities in the cash flow statement.

In the parent company, these costs have been reported as an increase in shares in subsidiaries.

Financing

The acquisition was financed with the company's own funds. A short-term loan of GBP 17 million (SEK 235.4 million as at December 31, 2024) was taken out in connection with the acquisition, which was repaid during the first quarter of 2025. In connection with this, dividend of GBP 36 million has been paid from IU to the parent company Surgical Science Sweden AB.

Revenue and contributions after the acquisition

For the period February 18 to September 30, IU contributed revenue of SEK 59.2 million and a net profit of SEK -19.3 million to the group. The profit includes restructuring costs of SEK 5.3 million.

Had the acquisition taken place on January 1, 2025, management estimates that the contribution to the group's revenue for the period January to September 2025 would have amounted to SEK 64.1 million and the contribution to the group's profit after tax for the same period would have amounted to SEK -34.2 million (excluding acquisition-related costs of GBP 1.2 million or SEK 16.4 million recognized in the period prior to the acquisition of IU).

Efficiency improvements

At the time of the acquisition, Surgical Science estimated that the efficiency gains that could be achieved would result in annual cost savings of between GBP 1.5 and 2.0 million (then corresponding to between SEK 20.3 and 27.0 million). Intelligent Ultrasound had sales of GBP 8.6 million in 2024 with an operating profit of GBP -2.7 million. The number of employees was 48. To date, annual cost savings of approximately GBP 2.5 million have been achieved relative to the cost structure that existed in the company at the time of acquisition. The savings primarily stem from lower costs related to the company's previous IPO and staffing reductions, mainly in the sales organization. These cost savings began to take effect during the second quarter. Restructuring costs of SEK 3.9 million (GBP 0.3 million) were recognized in the first quarter. During the third quarter, an additional SEK 1.5 million (GBP 0.1 million) was added, bringing total restructuring costs for the first nine months of the year to SEK 5.3 million (GBP 0.4 million).

For further information, please refer to press releases and the annual report for 2024.

Note 6. Goodwill

Reconciliation of goodwill in the group

SEK thousand	Jan 1 2025 - Sep 30, 2025	Jan 1, 2024 - Dec 31, 2024
Opening acquisition value	3,615,848	3,424,121
Acquisitions for the year	16,564	-
Revaluation at the balance sheet date	-489,030	93,533
Closing accumulated cost	3,143,382	3,517,654
Closing carrying amount	3,143,382	3,517,654

Definitions of key figures

Surgical Science believes that the key figures reported facilitate an understanding of the company's financial trends.

EBITDA margin

Operating profit less depreciation, amortization, and impairment of tangible and intangible assets as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Equity per share

Reported equity divided by the number of shares outstanding at the end of the period. The key figure gives an idea of how much capital per share is attributable to shareholders.

Average number of shares

The weighted average number of shares outstanding during the period.

Average number of shares after dilution

The weighted average number of shares outstanding during the period, adjusted for any dilution effect from warrants.

Adjusted EBIT margin

Operating profit less depreciation, amortization, and impairment of surplus values related to acquisitions as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Average number of employees

The number of employees recalculated as full-time positions per month divided by the number of months in the period.

Net sales growth, %

Percentage change in net sales between two periods. This key figure conveys a view of the sales trend between periods.

Earnings per share

Profit for the period in relation to the weighted average of the number of shares during the period.

Earnings per share after dilution

Earnings after tax per share adjusted for any dilution effect from warrants.

Operating profit

Profit before financial items and tax. This key figure shows the operating profit regardless of the financing structure and tax rate.

Operating margin

Operating profit as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Equity/assets ratio

Equity as a percentage of total assets. This key figure conveys a view of the extent to which the total assets have been financed by the owners.

Dividend per share

Dividend for the year divided by the number of shares outstanding on the date of payment of the dividend. Provides a picture of the value per share transferred to shareholders.

Profit margin

Profit for the year as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

surgicalscience

Head office

Surgical Science Sweden AB (publ)
Drakegatan 7A
SE-412 50 Gothenburg
Sweden
Phone: +46 31 741 65 60
E-mail: info@surgicalscience.com

Other offices in Sweden

Borgarfjordsgatan 6B
SE-164 55 Kista
Sweden
Phone: +46 31 741 65 60

Israel

3 Golan Street
Airport City, 7019900
Israel
Phone: +972 3 911 44 44

USA

Head office USA
23500 Mercantile, Suite F
Beachwood, Ohio 44122
USA
Phone: +1 800 918 1670

Other offices in the US

811 First Ave, Suite 408
Seattle, WA 98104
USA
Phone: +1 800 918 1670

United Kingdom

Hodge House
114-116 St Mary Street
Cardiff, CF10 1DY
United Kingdom
Phone: +44 29 2075 6534

Sales office, China

906, Excellence Century Center
Tower 3
2030 Jintian Road, Futian District,
Shenzhen
China 518026
Phone: +86 755 23985994